Leerink Partnrs Has Negative Outlook of BPMC FY2026 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Leerink Partnrs reduced their FY2026 earnings estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn $2.51 per share for the year, down from their prior estimate of $2.59. The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.63) per share. Leerink Partnrs also issued estimates for Blueprint Medicines' FY2027 earnings at $4.81 EPS.

BPMC has been the subject of a number of other research reports. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, November 8th. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Finally, Stephens reissued an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $123.72.

Blueprint Medicines Trading Down 2.0 %

NASDAQ:BPMC traded down $2.03 on Friday, reaching $101.97. 596,999 shares of the stock traded hands, compared to its average volume of 955,660. The firm has a market capitalization of $6.48 billion, a price-to-earnings ratio of -48.33 and a beta of 0.62. The company's 50 day moving average is $99.41 and its 200-day moving average is $94.78. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a 1-year low of $72.24 and a 1-year high of $121.90.

Institutional Trading of Blueprint Medicines

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new stake in Blueprint Medicines in the third quarter worth about $32,000. R Squared Ltd bought a new stake in Blueprint Medicines in the fourth quarter worth about $51,000. Covestor Ltd raised its position in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 403 shares during the period. Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $88,000. Finally, Van ECK Associates Corp raised its position in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 363 shares during the period.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 15,161 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now directly owns 14,967 shares in the company, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock valued at $4,984,696 in the last three months. 4.21% of the stock is currently owned by insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.